Technology area: Biotechnology & Pharmaceuticals
18 pending office actions • 11 art units • 18 examiners • 0 of 18 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Qiagen N.V. has 18 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 18 distinct examiners and 11 distinct art units, creating a broad prosecution footprint across the technology area. The examiner count matches the pending-action count, while the lower art-unit figure indicates that some examination groups handle matters involving different examiners.
BAUSCH, SARAE L is the busiest examiner, with 1 pending matter. No examiner has a larger concentration in the supplied data, so portfolio management should emphasize centralized tracking of distinct examiner records rather than relying on a single recurring contact.
For counsel, the art-unit distribution remains important when identifying recurring technical or procedural themes. At the same time, the dispersed examiner assignments make response consistency, claim-position documentation, and matter-level deadline control practical priorities for managing the pending biotechnology portfolio.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (11%) |
| §103 only | 5 (28%) |
| §102 only | 1 (6%) |
| §112 only | 1 (6%) |
| Double-patenting + other | 4 (22%) |
| Multi-statute (no §101) | 5 (28%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUSCH, SARAE L | 1 | 29.7% | +45.0% |
| BELLAH, JEFFREY LAWRENCE | 1 | 100.0% | +0.0% |
| LAU, JONATHAN S | 1 | 63.9% | -17.2% |
| CROW, ROBERT THOMAS | 1 | 41.6% | +32.5% |
| OLSON, ANDREA STEFFEL | 1 | 62.4% | -11.9% |
| KIM, YOUNG J | 1 | 64.8% | +18.2% |
| ALLEN, MICHAEL D | 1 | 31.9% | +48.8% |
| HORLICK, KENNETH R | 1 | 79.0% | +15.3% |
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| LU, FRANK WEI MIN | 1 | 62.7% | +67.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17344792 | METHOD FOR ISOLATING POLY(A) NUCLEIC ACIDS | HANEY, AMANDA MARIE | 42d overdue |
| 18029408 | PATHOGEN DETECTION METHOD | HORLICK, KENNETH R | 65d |
| 18717806 | SIGNAL NORMALIZATION OF NUCLEIC ACID AMPLIFICATION REACTION PRODUCTS | BAUSCH, SARAE L | — |
| 18702656 | HIGH STOKES SHIFT FLUORESCENCE DYES FOR MULTIPLEX DETECTION | BELLAH, JEFFREY LAWRENCE | — |
| 18029937 | METHOD FOR VIRUS DETECTION | KIM, YOUNG J | — |
| 17620615 | METHOD FOR SEPARATING NUCLEIC ACID MOLECULES BY SIZE | LAFAVE, ELIZABETH ROSE | — |
| 18255308 | COMPOSITIONS AND METHODS FOR DIAGNOSING SARS-COV-2 (COVID-19) AND FOR MONITORING SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY | CHEN, STACY BROWN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029408 | PATHOGEN DETECTION METHOD | HORLICK, KENNETH R | 65d |
| 18717806 | SIGNAL NORMALIZATION OF NUCLEIC ACID AMPLIFICATION REACTION PRODUCTS | BAUSCH, SARAE L | — |
| 18533836 | METHOD FOR ISOLATING NUCLEIC ACIDS FROM A FORMALDEHYDE RELEASER STABILIZED SAMPLE | CROW, ROBERT THOMAS | — |
| 18029937 | METHOD FOR VIRUS DETECTION | KIM, YOUNG J | — |
| 18029538 | EXTRACTION SOLUTION FOR PREPARING A BIOLOGICAL SAMPLE FOR AMPLIFICATION BASED PATHOGEN DETECTION | ALLEN, MICHAEL D | — |
| 17636582 | COMPOSITIONS AND METHODS FOR AMPLIFICATION OF STR LOCI | LU, FRANK WEI MIN | — |
| Art Unit | Apps |
|---|---|
| 1683 | 3 |
| 1693 | 3 |
| 1681 | 2 |
| 1684 | 2 |
| 1656 | 2 |
| 1699 | 1 |
| 1671 | 1 |
| 1682 | 1 |
| 1672 | 1 |
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18717806 | SIGNAL NORMALIZATION OF NUCLEIC ACID AMPLIFICATION REACTION PRODUCTS | BAUSCH, SARAE L | 1699 | §102§112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18702656 | HIGH STOKES SHIFT FLUORESCENCE DYES FOR MULTIPLEX DETECTION | BELLAH, JEFFREY LAWRENCE | 1683 | §101§102§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18570344 | METHOD FOR ISOLATING NON-VESICULAR MIRNA | LAU, JONATHAN S | 1693 | §103DP | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18533836 | METHOD FOR ISOLATING NUCLEIC ACIDS FROM A FORMALDEHYDE RELEASER STABILIZED SAMPLE | CROW, ROBERT THOMAS | 1683 | §103 | Final Rejection | — | Pending | Dec 08, 2023 |
| 18343296 | METHOD FOR ISOLATING RNA WITH HIGH YIELD | OLSON, ANDREA STEFFEL | 1693 | §103Other | Final Rejection | 4d overdue | Pending | Jun 28, 2023 |
| 18029937 | METHOD FOR VIRUS DETECTION | KIM, YOUNG J | 1681 | §102§103§112 | Non-Final OA | — | Pending | Apr 03, 2023 |
| 18029538 | EXTRACTION SOLUTION FOR PREPARING A BIOLOGICAL SAMPLE FOR AMPLIFICATION BASED PATHOGEN DETECTION | ALLEN, MICHAEL D | 1671 | §102§103§112DP | Non-Final OA | — | Pending | Mar 30, 2023 |
| 18029408 | PATHOGEN DETECTION METHOD | HORLICK, KENNETH R | 1681 | §102§103§112 | Non-Final OA | 65d | Pending | Mar 30, 2023 |
| 17785251 | METHOD FOR ENRICHING VESICULAR RNA | KRISHNAN, GANAPATHY | 1693 | §103DP | Final Rejection | 118d overdue | Pending | Jun 14, 2022 |
| 17636582 | COMPOSITIONS AND METHODS FOR AMPLIFICATION OF STR LOCI | LU, FRANK WEI MIN | 1683 | §102 | Final Rejection | — | Pending | Feb 18, 2022 |
| 17620615 | METHOD FOR SEPARATING NUCLEIC ACID MOLECULES BY SIZE | LAFAVE, ELIZABETH ROSE | 1684 | §102§103Other | Final Rejection | — | Pending | Dec 17, 2021 |
| 17416814 | URINE STABILIZATION | TSAY, MARSHA M | 1656 | §103DP | Non-Final OA | 74d overdue | Pending | Jun 21, 2021 |
| 17344792 | METHOD FOR ISOLATING POLY(A) NUCLEIC ACIDS | HANEY, AMANDA MARIE | 1682 | §103§112 | Non-Final OA | 42d overdue | Pending | Jun 10, 2021 |
| 18255308 | COMPOSITIONS AND METHODS FOR DIAGNOSING SARS-COV-2 (COVID-19) AND FOR MONITORING SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY | CHEN, STACY BROWN | 1672 | §101§112 | Non-Final OA | — | Pending | May 31, 2023 |
| 17421617 | Methods of Detecting Analytes and Compositions Thereof | RAYMONDA, MATTHEW HAROLD | 1684 | §103 | Final Rejection | 49d overdue | Pending | Jul 08, 2021 |
| 17276619 | DEPLETING UNWANTED RNA SPECIES | LEE, JAE W | 1656 | §103 | Final Rejection | — | Pending | Mar 16, 2021 |
| 17056393 | PROTECTION OF BIOLOGICALLY ACTIVE MOLECULES DURING RADIATION STERILIZATION | HENSEL, BRENDAN A | 1758 | §103 | Non-Final OA | 4d overdue | Pending | Nov 17, 2020 |
| 17049748 | BIOMOLECULE ISOLATION AND INHIBITOR REMOVAL | HIBBERT, CATHERINE S | 1658 | §112 | Final Rejection | — | Pending | Oct 22, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQiagen N.V. has 18 pending office actions as of October 2026, spread across 11 art units and 18 examiners.
Sarae L Bausch has the most, with 1 of Qiagen N.V.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
